

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
10 June 2004 (10.06.2004)

PCT

(10) International Publication Number
WO 2004/048988 A1

(51) International Patent Classification⁷: G01R 33/28, A61B 5/055

(74) Agents: FLECHSLER, Insa et al.; Amersham Health AS, Nycoveien 1-2, P.O. Box 4220 Nydalen, N-0401 Oslo (NO).

(21) International Application Number:
PCT/NO2003/000395

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(22) International Filing Date:
27 November 2003 (27.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
20025711 27 November 2002 (27.11.2002) NO

(84) Designated States (*regional*): ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): AMERSHAM HEALTH AS [NO/NO]; Intellectual Property Dept., Nycoveien 1-2, P.O. Box 4220 Nydalen, N-0401 Oslo (NO).

(72) Inventors; and

Published:

(75) Inventors/Applicants (*for US only*): AXELSSON, Oskar [SE/SE]; Amersham Health R & D AB, P.A. Hanssons v. 41, S-205 12 Malmö (SE). GOLMAN, Klaes [DK/DK]; Amersham Health R & D AB, P.A. Hanssons v. 41, S-205 12 Malmö (SE). MÅNSSON, Sven [SE/SE]; Amersham Health R & D AB, P.A. Hanssons v. 41, S-205 12 Malmö (SE). PETERSSON, Stefan [SE/SE]; Amersham Health R & D AB, P.A. Hanssons v. 41, S-205 12 Malmö (SE).

— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: METHOD OF MAGNETIC RESONANCE IMAGING

(57) Abstract: The present invention provides methods for passive visualisation of invasive devices by employing a hyperpolarised solution of a high T1 agent having a T1 value of at least 5 seconds at a field strength in the range of 0.001-5 T and a temperature in the range of 20-40 °C. Devices and instruments particularly useful for being employed in the methods are also provided as well as use of the methods in imaging, surgery and therapy.

WO 2004/048988 A1

Method of Magnetic Resonance Imaging

Field of the invention

The invention relates to magnetic resonance imaging (MRI) of invasive devices, e.g. during surgical and therapeutic procedures, and to devices for use with the procedures.

Description of related art

Interventional procedures in radiology are very common and increasingly popular. They are normally performed under fluoroscopic feedback by insertion of invasive instruments and/or devices like catheters, guide wires, biopsy needles, etc. through the blood vessels. The procedures can last for several hours and involve very high radiation doses for both the patient and the personnel performing them. During these procedures, it is desirable that the physician is able to locate or guide the invasive devices inserted into the patient's body when these devices are no longer visible. Since soft body parts give very little contrast on X-ray, it is often necessary to use high doses of iodinated contrast agents to localize the devices which in turn may cause problems, in particular for patients with reduced kidney function.

MRI-guided interventional procedures have gained increasing importance in recent years. Such MRI-guided procedures can be divided into two categories: intraoperative procedures, which integrate surgery with MRI, and interventional procedures for guiding, monitoring and controlling therapy. Intraoperative procedures generally require an open magnet MR imager and are desirable as the MRI can be used to define anatomy and monitor tissue function as it changes during surgery. Interventional procedures generally require only limited patient access and thus conventional, closed magnet MR imagers may be used. Normally, MRI a contrast agent or contrast medium is employed in such methods which enhances contrast and thus provides images of a higher quality. In the context of the present application, the terms "contrast agent" and "contrast medium" are used interchangeably.

- 2 -

The success of a MRI-guided interventional or intraoperative procedure generally depends on the ability of the MRI technique to provide accurate real time visualisation of the instruments and devices inserted into the patient's body. Generally most invasive devices are either metal based or made of polymeric materials, which is due to mechanical demands. Guide wires for example need to be stiff enough to enable them to be pushed past contortions and turns and to rotate as a rigid body all the way to the tip when the operator pushes and twists the other end, which is often a meter away from the tip of the wire. Hence guide wires are usually made of a steel core wound with a Teflon coated steel wire. However, when the device is metallic and/or conductive, it will act as a shield to the RF (radio frequency) irradiation and prevent it from reaching the contrast medium or agent within the device, thereby causing imaging defects in the region surrounding it. On the other hand, devices made of polymeric materials will not be visible in the MR image. It has been suggested to use non-conductive devices marked by incorporating bands of paramagnetic material such as for example dysprosium oxide. Such marker bands produce artefacts in the image. It has further been proposed to fill the instruments or devices with a paramagnetic contrast agent (e.g. GdDTPA) or a "blood pool" contrast agent, for example a ferromagnetic, ferrimagnetic or superparamagnetic contrast agent. The signal strength from such conventional MR contrast agents may however be inadequate for adequate "real time" tracking of the instrument. Furthermore, due to the toxicity of such agents, only limited amounts of agents may be administered or released into a living body. Another problem with this technology or, in fact, any technology that relies on proton imaging, is the massive background signal arising from water in the tissues and requiring either time consuming 3D data acquisition or dynamic slice positioning.

US-A-5,211,166 proposes visualisation of a part of an operative instrument by providing the instrument with a compound comprising a NMR active nucleus in, or in proximity to, the instrument. The NMR active nucleus can be any nucleus suitable for NMR, such as the NMR active isotopes of hydrogen, phosphorus, carbon, fluorine and nitrogen. Additionally, a paramagnetic relaxant is supplied and the signals of the NMR active nuclei are amplified by dynamic nuclear polarisation (DNP) to improve the

visibility of the instrument. However, it is difficult using *in vivo* polarisation enhancement as suggested in this document, at normal imager field strengths (>0.2 T), to achieve sufficient polarisation due to the limited penetration of the RF pulses through tissues and the instrument material, and thereby achieve a sufficient visualisation of the instrument. Another problem that occurs at higher fields is increased heating of the tissue surrounding the device. Furthermore, the amount of paramagnetic relaxant that can be released into living body tissue is also a constraint of this method due to potential toxicity of such materials.

WO-A-02/088766 proposes a method of monitoring the position of a medical instrument *in vivo* by introducing a hyperpolarised gas into a region within or adjacent to the instrument and imaging the hyperpolarised gas using NMR. The hyperpolarised gas can be dissolved in synthetic plasma, however only to a limited extent. ^{129}Xe and ^3He gases are specifically mentioned. Because of their low spin density, the MR sensitivity of hyperpolarised gases is significantly lower than that of a nucleus in a soluble molecule in a suitable solvent, given that other factors such as polarisation and magnetogyric ratio are similar.

Summary of the invention

Hence there was a need to provide improved methods for facilitating passive visualisation of invasive devices as well as a need for improved devices for use in such methods and utilisation of such methods in MR imaging, surgery and therapy. Related methods known from the prior art have drawbacks in that they expose the body under examination to high amounts of radiation, that distortions and artefacts in the MR image are unavoidable, that the contrast agents employed fail to provide the desired contrast or that they may have unacceptable toxicity at relevant doses.

It has now surprisingly been found that passive visualisation of invasive devices can be facilitated by employing a hyperpolarised solution of a high T_1 agent, i.e. an agent having a T_1 value of at least 5 seconds at a field strength in the range of 0.001-5 T and a temperature in the range of 20-40 °C during the time course of the visualisation

- 4 -

procedure. Hence the invention provides methods of facilitating the visualisation of invasive devices using such hyperpolarised solution of a high T1 agent. Further, devices and instruments particularly useful for being employed in these methods are also provided as well as the use of the methods in imaging, surgery and therapy.

Thus viewed from a first aspect, the invention provides a method of facilitating the visualisation of an invasive device in a human or non-human animal body by employing a contrast medium comprising a hyperpolarised solid high T1 agent or a solution thereof having a T1 value of at least 5 seconds at a field strength of 0.001-5 T and at a temperature of 20-40 °C and MRI is used for the visualisation of the invasive device.

Viewed from a further aspect, the invention provides a method of facilitating the visualisation of an invasive device in a human or non-human animal body comprising inserting the invasive device into said body, generating an MR image of at least a part of said body containing said device and introducing a contrast medium into and optionally through said device during the time course of the visualisation procedure, characterised in that the contrast medium comprises a hyperpolarised solid or solution of a high T1 agent having a T1 value of at least 5 seconds at a field strength of 0.001-5 T and at a temperature of 20-40 °C.

Viewed from a further aspect the invention provides an improved method of interventional or intraoperative MRI wherein an invasive device is inserted into a human or non-human animal body and an MR image of at least a part of said body containing said device is generated, said method comprising introducing a contrast medium into and optionally through said device during the time course of the visualisation procedure in order to facilitate visualisation of said device in said image, the improvement comprising in the contrast medium comprising a hyperpolarised solid or solution of a high T1 agent having a T1 value of at least 5 seconds at a field strength of 0.001-5 T and at a temperature of 20-40 °C.

- 5 -

Viewed from a further aspect the invention provides the use of a hyperpolarised solid or solution of a high T1 agent having a T1 value of at least 5 seconds at a field strength of 0.001-5 T and a temperature of 20-40 °C for the manufacture of a MR contrast medium for use in a method of diagnosis, surgery or therapy wherein an invasive device is inserted into of a human or non-human animal body, preferably into the tissue and/or vasculature, and an MR image of at least a part of said body containing said device is generated to visualise said device.

Viewed from a still further aspect the invention provides devices made of medium conductive material such as carbon fibre, e.g. carbon fibre composite material, for use in the methods according to the invention.

Further aspects of the invention will be evident from the claims and the specification.

The non-human animal body in the context of the present application can be a mammalian, avian or reptilian body. "T1" means the longitudinal relaxation time normally measured in seconds, and "T" means Tesla.

Detailed description of the invention

Contrast media for use in the methods of the invention comprise a hyperpolarised solid or solution of a high T1 agent, i.e. an agent having a T1 value of at least 5 seconds at a field strength of 0.001-5 T and at a temperature of 20-40 °C. Such agents are well known, e.g. from WO-A-93/35508 which is hereby included by reference.

Suitable high T1 agents will comprise nuclei with non-zero nuclear spin nuclei (polarisable nuclei) preferably nuclei selected from the group consisting of ^{19}F , ^6Li , ^{13}C , ^{15}N , ^{29}Si and ^{31}P in addition to ^1H . Particularly preferably, high T1 agents comprise nuclei selected from the group consisting of ^{13}C , ^{15}N , ^{19}F , ^{29}Si and ^{31}P nuclei, with ^{13}C and ^{15}N nuclei being particularly preferred. Other nuclei may also be used such as ^{77}Se , ^{111}Cd , ^{113}Cd , ^{115}Sn , ^{117}Sn , ^{119}Sn , ^{123}Te , ^{125}Te , ^{171}Yb , ^{195}Pt , ^{199}Hg , ^{203}Tl , ^{205}Tl and ^{207}Pb , in particular for contrast media that will only be administered to the body in small amounts

and concentrations or will not get into contact with the living body tissue, for example, by being held in a closed circuit inside the device during the procedure.

Preferred high T1 agents are biocompatible compounds with low toxicity. They may be used in solid form, e.g. as dispersions in a suitable solvent, but solutions of high T1 agents are preferably used, preferably in a biotolerable solvent. Particularly preferred high T1 agents are water-soluble molecules with a molecular weight below 200D (Dalton). The contrast media for use in the method according to the invention may comprise high T1 agents comprising polarisable nuclei either in their natural abundance. More preferred, the high T1 agents are enriched in a particular position of the molecule. Preferably, high T1 agents are enriched by ^{13}C and/or ^{15}N nuclei in one or more specific positions in the molecule. In a further preferred embodiment, these enriched high T1 agents are also deuterium labelled. Preferred ^{13}C enriched high T1 agents comprise one or more ^{13}C nuclei which is/are surrounded by one or more non-MR active nuclei such as O, S, C or a double bond, for example a high T1 agent being ^{13}C enriched at one or more carbonyl or quaternary carbons. Preferred compounds are compounds that occur naturally in the body such as amino acids, peptides, nucleic acids, carbohydrates and intermediates or metabolites occurring in the body's normal metabolic cycles and approved pharmaceuticals.

High T1 agents for use in ablation procedures include carboxylic acids and alcohols such as ethanol enriched with ^{13}C . Alternatively, ablation procedures can be performed with normal carboxylic acid and alcohol such as ethanol with a minor amount of polarised compound, e.g. a ^{13}C -labelled compound, added as a marker. For use in methods of therapy, suitable therapeutics preferably enriched with ^{13}C and/or ^{15}N may be used as high T1 agents, for example F-uracil and receptor targeting drugs.

Contrast media for use in the methods according to the invention preferably comprise hyperpolarised solids or solutions of high T1 agents, enriched with the mentioned nuclei and having a T1 relaxation time of 10 seconds or more, preferably 30 seconds or more, especially preferably more than 60 seconds and even more preferably more than 100

seconds at a field strength of 0.001-5 T and at a temperature of 20 to 40 °C.

Methods for producing hyperpolarised high T1 agents are known, e.g. from WO-A-99/35508 and WO-A-99/24080. Preferred methods comprise the Dynamic Nuclear Polarisation (DNP) method and the Parahydrogen (PHIP) method. By using these methods it is possible to obtain hyperpolarised high T1 agents having a T1 of 5 seconds or more.

"Invasive devices" mean any invasive device and instrument used in interventional procedures such as but not limited to catheters including balloon catheters, balloons, optical fibres, guide wires, needles e.g. biopsy needles, electrodes, electrode leads, implants and stents.

If it is desired to shield the contrast medium from RF (radio frequency) irradiation until the device filled with the contrast medium reaches the region of interest (ROI), it has been found that carbon fibre-containing material such as carbon fibre composite material can be employed. For instance using a catheter comprising carbon fibre material will prevent depolarisation of the contrast medium by the RF irradiation employed during the placement of the catheter. The contrast medium will thus remain "invisible" inside the device until it is released at the ROI. Furthermore, carbon fibre material has low electrical conductivity compared to metals and will not cause substantial imaging artefacts during imaging or tissue heating. Invasive devices made of carbon fibre materials are preferably used in the methods of the invention and such devices for use in the described methods form a further aspect of the invention.

The interventional or interoperative procedure according to the invention could start with the uptake of a 2- or preferably a 3-dimensional proton image of the part of the human or non-human animal body being examined. The invasive device, e.g. a catheter, is then introduced into the vasculature, e.g. the femoral artery, or into a tissue. When it is desired to visualise the device during the procedure, the device is preferably continuously filled with contrast medium through an external duct. The signal provided

by the contrast medium will allow real time visualisation and stereotactic location of the device in the 3D proton image. The proton image of the region of interest (ROI) can be updated during the procedure, e.g. to compensate for movements. It is also possible to inject doses of contrast medium into the vasculature or tissue during the introduction of the device into the body. For example, during the introduction of a catheter into an artery, it is possible to release doses of contrast medium from the device. In this way, it is for instance possible to examine the blood flow and the blood supply to an organ in real time. When the catheter has reached the region of interest, contrast medium can be released for facilitating the interventional or interoperable procedure, for example percutaneous transluminal angiography (PTCA) with a balloon catheter optionally combined with the placement of a stent in the affected part of the artery.

The method described in the paragraph above is particularly favourable for surgical and therapeutic procedures carried out in subjects or in parts or anatomical structures of the human or non-human animal body, that are particularly sensitive to radiation. Examples of such subjects are for instance pregnant women and small children, examples of such parts or anatomical structures are for instance reproductive organs. In women, about 40% of all fertility problems result from blocked fallopian tubes. The methods of the invention can therefore be utilised in procedures of examining the fallopian tubes and if necessary operating them to open such blockages interventionally by inserting a catheter through the vagina. This method forms a further aspect of the invention.

The described methods are also useful for diagnosis and precision biopsies of and surgery on solid tumours. In particular, tumours of the prostate and breasts could be sampled much more efficiently than with the currently used standard methods by using the methods according to the invention and thus simultaneously visualize soft tissue and allow precision guidance of for instance a biopsy needle.

The described methods can also be used in ablation procedures to guide the placement of clinically used devices, e.g. interstitial laser induced thermotherapy (LITT), focussed ultrasound and RF-ablation. In these procedures it is of utmost importance to place the

instrument used in exactly the correct position and to follow the ablation procedure, e.g. the destruction of solid tumours. By using a method in accordance with the present invention a catheter can be positioned exactly in the right position and the vessels and surrounding tissue, as well as the tumour or structure to be removed, can be monitored during the ablation procedure.

A further aspect of the invention involves using chemicals in the ablation procedures, either alone or together with the methods described above. When the device, e.g. a catheter, is placed in the correct position either by using a RF transparent catheter with a contrast medium or using a carbon fibre catheter, the catheter can be filled with a chemical substance effective in ablation procedures which contains, or is enriched with, hyperpolarisable nuclei. Such chemical substances are for instance carboxylic acids or alcohols. Alternatively, ablation can be performed with normal carboxylic acid or alcohol, e.g. ethanol, with a minor amount of a polarised compound, e.g. a high T1 agent, as a marker. The ablation procedure can then be monitored by MRI. ^{13}C or ^{15}N enriched compounds are preferred, e.g. ^{13}C enriched ethanol can be hyperpolarised and used for this purpose.

A further aspect of the invention is related to utilising the methods of the invention in therapy. As described above, a device such as a catheter can be exactly placed in the region in need of treatment and a hyperpolarisable compound, preferably a compound enriched with polarisable nuclei such as ^{13}C and/or ^{15}N , can be instilled at the site. The effect of the treatment can then be followed with MRI. Examples of compounds comprise F-uracil, e.g. ^{13}C enriched and receptor targeting drugs (e.g. peptides) or bactericides, fungicides etc. The contrast medium will hence have a dual function as contrast medium and therapeutically active medium. Alternatively the therapeutically active compound can be a normal therapeutic compound containing a minor amount of polarised compound which works as a contrast medium.

Imaging parameters such as pulse sequences should be chosen carefully to achieve optimal results of the methods described above. Many methods for fast proton imaging

- 10 -

are standardised on modern MRI scanners and it is obvious to one skilled in the art how to re-write the software to be suitable for other nuclei. Especially suitable methods are spiral and radial scan k-space sampling, optionally with sliding window update of the image. An additional option is the use of interleaved stereoscopic projections to allow for real-time stereoscopic visualisation by means of red-green stereo glasses or any of the many known stereo visualisation techniques.

The invention will be illustrated below by means of non-limiting examples and/or embodiments.

Description of the Figures:

Figure 1 shows a first embodiment of an invasive device in accordance with the present invention.

Figure 2 shows a carbon fibre tube as described and used in Example 2.

Figure 3 shows a second embodiment of an invasive device in accordance with the present invention.

Figures 4a - 4d show schematically cross-sections through further embodiments of invasive devices in accordance with the present invention.

Figure 5 shows the stomach of a rat into which a guide wire has been inserted as described in Example 1.

Figure 6 shows an X-ray angiogram of a catheter placed in the left coronary artery of a pig.

Figure 7 shows a series of ^{13}C MR images obtained during simultaneous retraction of a catheter from the left coronary artery of a pig and injection of a contrast medium comprising a hyperpolarised high T1 agent as described in Example 4

Figure 8 shows a series of ^{13}C MR images obtained during injection of a contrast medium comprising a hyperpolarised high T1 agent through a catheter inserted into the left coronary artery of a pig as described in Example 5.

Figure 9a shows a ^{13}C MR image obtained using retrospective gating during an injection of a contrast medium comprising a hyperpolarised high T1 agent through a catheter inserted into the left coronary artery of a pig as described in Example 6.

Figure 9b shows the non-hyperpolarised proton image corresponding to figure 9a.

Figure 1 shows a first embodiment of an interventional MRI invasive device (1) for use with a contrast medium comprising a hyperpolarised high T1 agent in accordance with the present invention. The invasive device (1) comprises a hollow, elongated body (3) of a diameter D mm. The body (3) has a central lumen (5) and a wall (7) of a thickness d mm. The invasive device (1) is intended to be inserted into the body of a human or non-human animal and thus may be made rigid or flexible depending on what it is used for, e.g. rigid if it is to be used as a needle and flexible if it is to be used as a catheter. The body (3) is made of carbon fibre containing material such as carbon fibre composite material, which has been found to be opaque to RF irradiation (as further described below). This is surprising because carbon fibre composite materials are normally considered to be insulating, as their electrical conductivities are almost 600 times less than that of copper.

In this embodiment, the invasive device (1) is suitable for transporting contrast medium comprising a hyperpolarised high T1 agent from a first open end, which is intended to be outside the human or non-human animal body and which is preferably connectable to a supply of contrast medium, to a second open end, which is intended to be inside or inserted into the human or non-human animal body and from which the contrast medium may be released into the ROI, for example into a blood vessel or body cavity. As the invasive device (1) is opaque to RF irradiation, the contrast medium comprising a hyperpolarised high T1 agent will not be depolarised by RF irradiation while it is shielded by the body (3).

When it is desired to visualise the devices during the entire procedure, the devices should be made of material transparent for RF (radio frequency) irradiation to provide sufficient signals from the contrast medium inside the device. Glass fibre reinforced polymer material is known to have suitable physical properties for devices such as guide wires, optical fibres, electrodes and electrode leads. Other construction polymers such as PEEK or PSU also have suitable characteristics. Needles and similar devices can be made of ceramic material such as dense zirconia, optionally coated with a polymer layer

- 13 -

to make it less brittle or of glass fibre reinforced plastic material. Devices lacking a cavity for containing a contrast medium should be fitted with a cavity, preferably a cavity extending along the length of the device and preferably facilitating circulation of the contrast medium. Catheters may, for example, be made with double walls to allow and provide contrast medium circulation. The refill of contrast medium into the device through an external duct during the procedure will also be possible with such arrangements.

Figure 3 shows a second embodiment of an interventional MRI invasive device (31) for use with a contrast medium comprising a high T1 agent in accordance with the present invention. The invasive device (31) comprises a hollow, elongated body (33) of a diameter D mm and a wall (37) of a thickness d mm. The body (33) comprises a first lumen (35') and a second lumen (35'') which both extend from an open first end (39) of the body (33) to a closed second end (41) of the body (33). The first lumen 35' and the second lumen 35'' are formed on either side of a central interior dividing wall (43) which extends from one side of the interior surface of body (33) to the, preferably diametrically, opposite side of the interior surface of body (33).

The interior dividing wall (43) does not extend all the way to the closed second end (41), thus the first (35') and second (35'') lumen are in communication near the second end (41) of the device (31) through an opening (45) in the dividing wall (43). This allows a fluid, e.g. introduced into the first lumen (35') at the open first end (39) to circulate along the length of the first lumen (35), then pass through the opening (45) in the dividing wall (43) near to, or at, the closed second end (41) and return via the second lumen (35'') to the open first end (39). For use in an interventional procedure, device (31) is preferably made from a material transparent to RF irradiation and a contrast medium, preferably a contrast medium comprising a hyperpolarised high T1 agent, is circulated in the invasive device (31) by being introduced through the first lumen (35') and extracted via the second lumen (35''). In such a way new contrast medium can be introduced into the device (31) as old contrast agent is extracted from it.

- 14 -

In a further embodiment of the present invention, an invasive device comprising a hollow, elongated body is provided with a third lumen, which extends to the end of the device, which is intended to be introduced into a patient. This lumen can be used to accommodate a guide wire, which is used to position the device.

In another further embodiment of the present invention, an invasive device comprising a hollow, elongated body and a first and second lumen (e.g. like the device shown in figure 3) is provided with a third lumen, which extends to that end of the device that is intended to be introduced into the human or non-human body. This third lumen can be open at the end intended to be introduced into the human or non-human body and can be used to accommodate a tool. For example the third lumen could be provided with an inflatable balloon which can be inflated once the device has been manoeuvred to a suitable position inside the body. Alternatively the lumen could accommodate a biopsy needle, a stent or the like. An example of such a device can be seen in cross-section in figure 4a.

In another embodiment of the present invention, an invasive device is provided with more than three lumens, of which two may be made interconnecting to allow the circulation of a fluid, e.g. a contrast medium and the others may be used for introducing tools and/or fluids into a human or non-human body. An example of such a device can be seen in cross-section in figure 4c.

Examples

The following non-limiting examples illustrate features of the invention.

Example 1

An aqueous solution of hyperpolarised dimethylsuccinate ($1\text{-}^{13}\text{C}$) was circulated in a closed loop moulded in a guide wire of glass-fibre reinforced plastic. The T_1 of this compound under these circumstances is 70 s. The guide wire was inserted in the stomach of a rat and was imaged at the ^{13}C frequency at 4 images per second. The images were colour coded and overlaid with a proton image of the rat. The guide wire is clearly visible in the rat as can be seen from the image in Figure 5.

Example 2

Figure 2 shows the results of an experiment carried out using an invasive device (1) with a body (3) made from carbon fibre with a diameter D of 10 mm and a wall (7) thickness d of 1 mm. The electrical conductivity of the carbon fibre was $\sim 1 \cdot 10^5$ S/m (c.f. copper: $5.9 \cdot 10^7$ S/m). Device (1) was placed in a syringe containing water and imaged inside a 2.4 T magnet. Gradient echo images were acquired with echo time 1.8 ms as shown in Figure 2a and 5 ms as shown in Figure 2b. Similar results were obtained with both echo times. Minor susceptibility artefacts (13) can be seen near the second open end of the invasive device. No signal is obtained from the lumen (3) of the of the device (except near to the second open end where radio frequency radiation has entered the lumen (3) from said second open end) showing that the wall of the invasive device is opaque to radio frequency radiation.

Example 3

Examples of possible embodiments of invasive device cross-sections are shown in figures 4a – 4d.

Figure 4a shows an invasive device formed of two concentric tubes (401, 403) with the inner tube (403) held in place in the centre of the outer tube (401) by an open system of

webs (405). A first lumen (407) is formed in the interior of said inner tube and a second lumen (409) is formed by the annular space between the two tubes (401, 403).

Figure 4b shows an invasive device formed of two concentric tubes (411, 413), with the inner tube (413) held in place in the centre of the outer tube (411) by two continuous webs (415', 415''). A first lumen (417) is formed in the interior of said inner tube (413) and a second lumen (419') and a third lumen (419'') are formed by the semi-annular space between the two tubes (411, 413) and the webs (415', 415'').

Figure 4c shows an invasive device comprising an elongated body (421) with four lumens (423) formed in it.

Figure 4d shows an invasive device comprising an elongated body (431) with a central lumen (433) and two crescent shaped lumens (435', 435'') attached to the outer wall of said body (431).

Preferably the dimension D of the body of these devices is less than 20 mm, most preferably below 10 mm and greater than 1 mm, and the dimension d (wall thickness) of the body of said devices is preferably less than $D/5$ and most preferably less than $D/10$.

Further embodiments and modifications of invasive devices are also possible under the scope of the following claims.

Example 4

Preparation

A catheter (Cobra, M, Fr.5, Terumo Europe N.V. 3001 Leuven, Belgium) was placed into the left coronary artery of a pig. Correct localisation of the catheter was confirmed by X-ray imaging using a mobile X-ray arm, a standard X-ray contrast agent was used. Figure 6 shows the X-ray angiogram obtained. An aqueous solution of hyperpolarised hydroxyethylpropionate ($1\text{-}^{13}\text{C}$) was prepared and used as contrast medium, the polarisation was about 28%, and the concentration of hydroxyethylpropionate ($1\text{-}^{13}\text{C}$)

was about 0.5 M. For MR imaging, a 1.5 Tesla scanner (Magnetom Sonata, Siemens Medical Solutions, Erlangen, Germany) equipped with multi nuclei extension together with a transmit/receive ^{13}C coil (RapidBiomedical, Würzburg, Germany) was used. In order to select projection angels for the FOV in question, standard proton scans were employed. ^{13}C images were obtained using a fully balanced steady state pulse sequence.

Conduction of the interventional procedure

^{13}C images (shown in figure 7) were acquired while the catheter was retracted from the coronary artery and at the same time the contrast medium was injected through the catheter. The following imaging parameters were used: TR/TE/FA = 5.6 ms / 2.8 ms / 70° and FOV / Matrix = $128 \times 256 \text{ mm}^2$ / 64×128 . No gating was used and each image was generated in 350 ms. Figure 6 clearly demonstrate the ability of the method of the invention to visualize a catheter during in an interventional procedure.

Example 5

Preparation was carried out as described in Example 4.

Conduction of the interventional procedure

^{13}C images (of which 5 extracted images are shown in figure 8) were acquired during injection of the contrast medium through the catheter. Cardiac gating was applied and one image was generated per heart cycle. The following imaging parameters were used: TR/TE/FA = 5.1 ms / 2.6 ms / 70° and FOV / Matrix = $112 \times 256 \text{ mm}^2$ / 56×128 . Each image was generated in 350 ms. Image e in figure 8 shows the myocardium, suggesting that perfusion data may also be extracted from the imaging data in addition to angiography.

Example 6

Preparation was carried out as described in Example 4.

Conduction of the interventional procedure

^{13}C images (of which one is shown in figure 9a) were acquired during injection of the

- 18 -

contrast medium through the catheter. Retrospective gating was applied. This method reorganizes the image data according to the simultaneously acquired cardiac gated signal. The cardiac cycle (systole-diastole) was divided into 22 phases and 16 were reconstructed. Imaging data from more than one heart beat were represented in each of the images of the series. For a spatial resolution of $2.0 \times 2.0 \text{ mm}^2$ approximately 10 heart beats were needed to complete each series. The following imaging parameters were used: TR/TE/FA = 5.1 ms / 2.6 ms / 70° and FOV / Matrix = $128 \times 256 \text{ mm}^2$ / 64×128 . The total scan time was 8 s. A comparison image series was acquired using standard non-hyperpolarised proton imaging. Figure 9a shows one ^{13}C image out of the series of 16 phases in the cardiac cycle. The perfusion of the cardiac muscle is evident. The corresponding non-hyperpolarised proton slice is shown in figure 9b.

Claims

1. Use of a hyperpolarised solid or solution of a high T1 agent having a T1 value of at least 5 seconds at a field strength of 0.001-5 T and a temperature of 20-40 °C for the manufacture of a MR contrast medium for use in a method of diagnosis, surgery or therapy wherein an invasive device is inserted into a human or non human animal body and an MR image of at least a part of said body containing said device is generated to visualise said device.
2. Use as claimed in claim 1 wherein said high T1 agent comprises nuclei with non-zero spin nuclei, preferably nuclei selected from the group consisting of ^{19}F , ^6Li , ^{13}C , ^{15}N , ^{29}Si and ^{31}P , particularly preferably nuclei selected from the group consisting of ^{13}C , ^{15}N , ^{19}F , ^{29}Si and ^{31}P nuclei and most preferably nuclei selected from the group consisting of ^{13}C and ^{15}N nuclei.
3. Use as claimed in claim 1 wherein said high T1 agent comprises the nuclei selected from the group consisting of ^{77}Se , ^{111}Cd , ^{113}Cd , ^{115}Sn , ^{117}Sn , ^{119}Sn , ^{123}Te , ^{125}Te , ^{171}Yb , ^{195}Pt , ^{199}Hg , ^{203}Tl , ^{205}Tl and ^{207}Pb .
4. Use as claimed in claims 1 to 3 wherein said high T1 agent have a T1 value of at least 10 seconds or more, preferably 30 seconds or more, more preferably 60 seconds or more and most preferably of more than 100 seconds at a field strength of 0.001-5 T and a temperature of 20-40 °C.
5. Use as claimed in any of claims 1 to 4 wherein the invasive device contains a cavity for holding the contrast medium, the cavity preferably fitted with an outside duct for facilitating circulation and addition of contrast medium.
6. Use as claimed in any of claims 1 to 5 wherein said invasive device is made from a medium conductive material containing carbon fibre.



7. Use as claimed in any of the preceding claims wherein the invasive device is inserted into a tissue and/or vasculature of the human or non-human animal body.
8. Use as claimed in any of the preceding claims wherein the contrast medium additionally is a therapeutically active medium.
9. Use as claimed in claim 8 where the therapeutic active medium is instilled at the region of interest via the invasive device.
10. Use as claimed in any of the preceding claims wherein the method is a method of examining and optionally operating the fallopian tubes.
11. Use as claimed in any of claims 1 to 9 wherein the method is a method for diagnosis and optional surgery on tumours.
12. Use as claimed in any of claims 1 to 9 wherein the method is a method for diagnosis by biopsy, preferably breast or prostate biopsy.
13. Use as claimed in any of claims 1 to 8 wherein the method is an ablation procedure where an additional compound effective in this ablation procedure is introduced through the invasive device.
14. A method of facilitating the visualisation of an invasive device in a human or non-human animal body comprising inserting the invasive device into said body, generating an MR image of at least a part of said body containing said device and introducing a contrast medium into and optionally through said device during the time course of the visualisation procedure, characterised in that the contrast medium comprises a hyperpolarised solid or solution of a high T1 agent having a T1 value of at least 5 seconds at a field strength of 0.001-5 T

- 21 -

and at a temperature of 20-40 °C.


15. Invasive device, for use with the contrast medium and in the methods of the preceding claims comprising a hollow elongated body made from carbon fibre containing material.
16. Invasive device according to claim 15 characterised in that the hollow elongated body is opaque to radio frequency radiation.
17. Invasive device according to claim 15 characterised in that the hollow elongated body is made of carbon-fibre composite material
18. Invasive device for use with the contrast medium and in the method of claims 1 to 14 comprising a hollow elongated body with a first end and a second end, a first lumen extending from said first end to said second end and a second lumen extending from said first end to said second end, characterised in that said first lumen is in communication with said second lumen near to said second end.
19. Invasive device according to claim 18 characterised in that it comprises more than 2 lumens.
20. Invasive device according to claims 18 and 19 characterised in that the hollow elongated body is opaque to radio frequency radiation.

1/6



TE = 1.8 ms

Fig. 2a



TE = 5 ms

Fig. 2b





Fig. 4a




Fig. 4b




Fig. 4c




Fig. 4d

Fig. 5






Fig. 6




Fig. 7




Fig. 8





Fig. 9

INTERNATIONAL SEARCH REPORT

International Application No

PCT/NO 03/00395

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 G01R33/28 A61B5/055

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 G01R A61B A61K A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, INSPEC

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 35508 A (LEUNBACH IB ;COCKBAIN JULIAN (GB); NYCOMED IMAGING AS (NO); HANSSO) 15 July 1999 (1999-07-15) cited in the application abstract; claims 5,25-34	1,2,4
Y		6,7,11, 12,14, 15,17
Y	WO 98 22022 A (ITI MEDICAL TECHNOLOGIES INC) 28 May 1998 (1998-05-28)	6,7,11, 12,14, 15,17
A	page 12, line 11 -page 15, line 11 page 17, line 6 -page 21, line 29	1

	-/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

22 March 2004

Date of mailing of the international search report

05.04.04

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

BO GUSTAVSSON/MN

INTERNATIONAL SEARCH REPORT

International Application No

P 03/00395

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	US 5 154 179 A (RATNER ADAM V) 13 October 1992 (1992-10-13) column 5, line 23 -column 7, line 3 ---	18,19
A	WO 02 088766 A (HANLEY PETER ;OXFORD INSTR PLC (GB)) 7 November 2002 (2002-11-07) see whole document, cited in the application ---	1,5,7, 10-14,18
A	US 5 211 166 A (SEPPONEN RAIMO) 18 May 1993 (1993-05-18) see whole document, cited in the application -----	1,5,7, 10-14,18

INTERNATIONAL SEARCH REPORT

International application No.
PCT/NO 03/00395

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 14
because they relate to subject matter not required to be searched by this Authority, namely:
see FURTHER INFORMATION sheet PCT/ISA/210
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.1

Claims Nos.: 14

Claim 14 relates to a method of treatment of the human body by surgery or by therapy/ a diagnostic method practised on the human or animal body/Rule 39.1(iv). Nevertheless a search has been executed for this claim. The search has been based on the alleged effects of the compound(s)/product/device.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/NO 03/00395

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
WO 9935508	A	15-07-1999	AU 1047399 A	31-05-1999
			AU 752308 B2	12-09-2002
			AU 1775399 A	26-07-1999
			AU 8119298 A	04-01-1999
			BR 9813244 A	10-10-2000
			CA 2290808 A1	23-12-1998
			CA 2317526 A1	15-07-1999
			CN 1269015 T	04-10-2000
			CN 1138154 C	11-02-2004
			CN 1306441 T	01-08-2001
			EP 0990168 A1	05-04-2000
			EP 1047455 A1	02-11-2000
			EP 1046051 A1	25-10-2000
			WO 9858272 A1	23-12-1998
			WO 9924080 A1	20-05-1999
			WO 9935508 A1	15-07-1999
			HU 0102093 A2	28-09-2001
			JP 2002508687 T	19-03-2002
			JP 2001522819 T	20-11-2001
			JP 2002501006 T	15-01-2002
			NO 996173 A	15-02-2000
			NO 20002429 A	10-05-2000
			NO 20003251 A	22-06-2000
			NZ 505151 A	26-11-2002
			US 6278893 B1	21-08-2001
			US 2004024307 A1	05-02-2004
			US 6311086 B1	30-10-2001
			US 6574495 B1	03-06-2003
			US 6466814 B1	15-10-2002
WO 9822022	A	28-05-1998	US 5782764 A	21-07-1998
			AU 3592597 A	10-06-1998
			WO 9822022 A1	28-05-1998
US 5154179	A	13-10-1992	US 4989608 A	05-02-1991
WO 02088766	A	07-11-2002	WO 02088766 A1	07-11-2002
US 5211166	A	18-05-1993	FI 80585 B	30-03-1990
			DE 3937052 A1	17-05-1990
			JP 2198540 A	07-08-1990